Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a report published on Thursday,Benzinga reports. They currently have a $6.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a report on Monday, December 9th.

Artelo Biosciences Stock Performance

Artelo Biosciences stock opened at $1.07 on Thursday. Artelo Biosciences has a 52 week low of $0.91 and a 52 week high of $1.70. The stock has a market capitalization of $3.45 million, a P/E ratio of -0.37 and a beta of 1.25. The stock has a fifty day moving average of $1.16 and a 200-day moving average of $1.16.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.